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the extended luteal regression observed in both pregnant and non-pregnant cycles, active luteolysis is
observed only in pregnant dogs. Luteal regression in the absence of pregnancy lacks a luteolytic trigger.
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are already available in the first half of diestrus, LH and especially prolactin (PRL) play a decisive
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factors are orchestrated to ensure a fully functional CL, which in the bitch produces progesterone (P4),
17b-estradiol, and other local regulators. Recently, insulin has been described as another luteotropic
factor in this species, able to increase glucose uptake in luteal cells and contribute to steroid biosynthesis.
The locally-produced PGE2 is also a potent luteotropic factor in the first half of diestrus, promoting
STAR expression, as are also proliferating, vasoactive- and immunomodulatory factors. These, in turn,
all contribute to the formation and maintenance of the canine CL. Meanwhile PGF2a, produced by the
utero-placental compartment, participates actively in triggering pre-partum luteolysis. Cytokines play
different roles, either contributing as luteotropic or as acute inflammation molecules. So far, the one
clinically most efficient mechanism of interrupting a pregnancy in the dog is to block P4 receptors, using
an antigestagen (e.g., aglepristone) in the second half of diestrus. To enhance the chances of pregnancy,
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a b s t r a c t
The fate of the canine corpus luteum (CL) differs from that of other domestic species: beyond the
extended luteal regression observed in both pregnant and non-pregnant cycles, active luteolysis is
observed only in pregnant dogs. Luteal regression in the absence of pregnancy lacks a luteolytic trigger.
The CL lifespan during pregnancy is around 60 days, as long as that of the cyclic CL. Although they are
already available in the first half of diestrus, LH and especially prolactin (PRL) play a decisive luteotropic
role from approximately day 25 post-ovulation onwards. Nevertheless, many locally-produced factors are
orchestrated to ensure a fully functional CL, which in the bitch produces progesterone (P4), 17b-estradiol,
and other local regulators. Recently, insulin has been described as another luteotropic factor in this
species, able to increase glucose uptake in luteal cells and contribute to steroid biosynthesis. The locally-
produced PGE2 is also a potent luteotropic factor in the first half of diestrus, promoting STAR expression,
as are also proliferating, vasoactive- and immunomodulatory factors. These, in turn, all contribute to the
formation and maintenance of the canine CL. Meanwhile PGF2a, produced by the utero-placental
compartment, participates actively in triggering pre-partum luteolysis. Cytokines play different roles,
either contributing as luteotropic or as acute inflammation molecules. So far, the one clinically most
efficient mechanism of interrupting a pregnancy in the dog is to block P4 receptors, using an anti-
gestagen (e.g., aglepristone) in the second half of diestrus. To enhance the chances of pregnancy, how-
ever, several luteotropic factors could be used.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The dog is unique among domestic species with regard to the
evolution of reproduction. Cyclic diestrus lasts at least 60 days [1,2],
i.e., as long as pregnancy or longer, and the corpus luteum (CL) plays
the central role in regulating the estrous cycle and pregnancy. Since
the dog placenta is unable to produce steroid hormones [3,4],
crucial for successful pregnancy, and the canine CL is the only
source of progesterone (P4) and 17b-estradiol (E2) during diestrus
[5], the CL should be among the main foci of research in the dog
when the aim is to manipulate pregnancy.
Hormones control the CL lifespan, either in an endocrine or
paracrine/autocrine way [5e8]. Locally produced growth factors,
cytokines and prostaglandins (PGs), modulate CL function, creating
a balance leading to luteal regression in non-pregnant dogs or
luteolysis in pregnancy (reviewed in Ref. [9]). In pregnant dogs, the
trophoblast is the feto-maternal compartment most responsible for
PGF2a production [10], which actively participates in pre-partum
luteolysis. Aglepristone is a P4 receptor (PGR) blocker, which can
be safely used to terminate pregnancy in dogs by evoking pre-term
parturition/abortion [11]. Alternative methods are desirable, espe-
cially ones related to manipulating cyclicity and avoiding preg-
nancy. Neutering is a surgical approach, broadly used for control of
street dog populations, but is considered very invasive, as well as
expensive when applied on a mass scale [12]. On a smaller scale,
but still very important for understanding canine pregnancy
physiology, pregnancy failures are often observed due to luteal
insufficiency [13], which raises the need to develop tools to
improve that particular situation.
Regardless of the approach, and before discussing this question,
we shall review the major general and local players controlling the
CL lifespan in cyclic and pregnant dogs (summarized in Table 1),
and then identify possible target mechanisms to increase the
chances of pregnancy in the dog or of avoiding it.
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Table 1
Luteotropic factors and those involved in luteolysis or regression of the pregnancy and cyclic canine corpus luteum.
Luteotropic
Factors
Pregnancy CL Cyclic CL
Pre-implantation Post-implantation Mid gestation Pre-Partum luteolysis Formation Maintenance Early regression Late regression
LH 1.7 ng/mL 1.7 ng/mL 1.7 ng/mL 2.3 ng/mL 1.5 ng/mL 1.5 ng/mL 1.5 ng/mL 1.7 ng/mL
LH receptor increase until mid gestation ¼ ¼
Prolactin-PRL constant increase until 50 ng/mL 2e4 ng/mL ¼ ¼ 9 ng/mL
PRL receptor constant expression until gradually decreasing
Insulin * * * * 3.8 uU/mL 2 uU/mL 5 uU/mL 1.7 uU/mL
GLUT4 * * * * ¼
GLUT1 * * * * ¼ ¼
Progesterone variably high, similar to non-pregnant <2e3 ng/mL Variably high, similar to pregnant >1 ng/mL levels <1 ng/ml
indicate onset of anestrus
PGR constant constant higher lower/
constant
lower/constant higher
17b-estradiol 21e42 pg/mL 21e42 pg/mL 21e42 pg/mL <12 pg/mL 12e20 pg/mL 20e35 pg/mL 30e40 pg/mL 20-12 pg/mL
ERa * * * * constant constant constant
ERb * * * * constant expression throughout diestrus




EP2 constant expression until ¼ ¼
EP4 constant constant constant expression throughout diestrus
IL-6 * * * * ¼ ¼
IL-10 * * * * * * *
VEGFA ¼ ¼ ¼ ¼
VEGFR1 ¼ ¼ ¼
VEGFR2 constant expression throughout diestrus ¼
FGF2 * * * *
Endothelin 1 constant expression throughout diestrus ¼ ¼
ETB ¼ ¼ ¼ ¼
ECE1 constant expression until ¼ ¼
IGF1 ¼ ¼
IGFR1 constant expression until constant expression throughout diestrus
Factors involved with Pregnancy CL Cyclic CL




Mid gestation Pre-Partum luteolysis Formation Maintenance Early regression Late regression
PGFM 200 pg/mL 700 pg/mL 1000 pg/mL 7900 pg/mL 900 pg/mL 500 pg/mL ¼ 200 pg/mL
PTGFR constant expression throughout diestrus Stable expression throughout diestrus
PGFS low ¼ ¼ low or no detection
IL-1b * * * constant expression throughout diestrus
IL-8 * * * * * * *
IL-12a * * * constant expression throughout diestrus
CCL3 * * * * * * *
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2. Classical endocrine regulators of luteal function
2.1. Prolactin and luteinising hormone
Luteinizing hormone (LH) triggers a marked preovulatory
luteinization of canine follicular granulosa and theca interna cells.
Independent of pregnancy, the canine CL may last as long as
pregnancy (approximately 60 days) or longer, and is able to
respond to LH and PRL, particularly in the second half of diestrus
[14,15], when concentrations of both gonadotropins increase in
peripheral blood [6,7]. Accordingly, immunoneutralization of LH
during the second half of diestrus in non-pregnant dogs and during
pregnancy was associated with a transient decline in serum P4
concentrations, but was not able to abbreviate the CL lifespan [16].
However, LH was reported to increase circulating PRL levels in
canine pregnancy, placing LH in an indirect luteotropic role [7]. In
the cyclic CL, LH receptors (LHR) were assessed at the mRNA level,
showing an increase fromday 5 up to days 15 and 25 post-ovulation
(p.o.), and a decrease thereafter at day 35 p.o., with no significant
changes until day 65 p.o. Interestingly, in the same study, LHR
mRNA in the pregnancy CL increased from pre-implantation to
mid-gestation and remained so until pre-partum luteolysis [17].
In non-pregnant dogs, plasma PRL concentrations fluctuate
constantly around 2e4 ng/mL during diestrus and rise slightly to
9 ng/mL on day 60 p.o. However, PRL increases continuously in
pregnant dogs towards the end of gestation, achieving 50 ng/mL
close to parturition [15]. PRL receptors (PRLR) are expressed in
cyclic and gestational canine CLs: during the estrous cycle the
expression of PRLR increases from day 5e15, and decreases grad-
ually towards day 65 p.o. Similarly, in pregnancy, PRLR expression is
high in the developing CL and decreases gradually during luteal
regression until mid-gestation (approximately day 35e40), and is
strongly suppressed at pre-partum luteolysis [17]. Moreover, in
isolated canine early luteal cells (approximately 3 weeks p.o.)
prostaglandin E2 (PGE2) strongly stimulated PRLR expression [18].
In the same report, functional withdrawal of prostaglandin activity
during the early luteal phase, associated with decreased intraluteal
PGE2 synthesis, significantly diminished in vitro PRLR expression
[18]. This apparent functional loop implies an indirect involvement
of PGE2 in regulating sensitivity of the canine CL to circulating PRL.
Nevertheless, during the first half of the diestrus phase, i.e., from
the day of ovulation until approximately day 24e28, the canine CL
is independent of the potential luteotropic action of hypophyseal
hormones [19] and hypophysectomy triggers only a transient
decline in concentrations of plasma P4. After day 24 p.o., hypo-
physeal ablation and/or blockade of PRLR leads to luteolysis in the
non-pregnant dog, further highlighting the role of PRL in regulating
the CL lifespan [19,20]. Additionally, as a pleiotropic hormone,
plasma PRL is able to modulate glucose homeostasis and insulin
secretion, as shown in rats [21]. However, in humans, high doses of
PRL (hyperprolactinemia) can cause insulin resistance and act as a
diabetogenic hormone [22].
2.2. Progesterone and 17b-estradiol
In cows, E2 acts as an endocrine modulator of the cyclic CL
lifespan [23]. It is produced by the recruited growing ovarian fol-
licles during the follicular waves [24]. The system of ovarian ve-
nules and veins carries E2 into the main blood circulation, which
then distributes E2 throughout the target organs, including the
ovary containing the CL. Possible paracrine and autocrine effects of
E2 on the bovine cyclic CL may not be excluded, since ovarian
arterio-venous anastomoses exist [25,26], and the CL itself has been
reported to produce E2 [27]. Together with PGF2a (prostaglandin F2
alpha), E2 can be considered a luteolytic factor in cows [28]. In
pregnant cows, however, ovarian E2 production is maintained at
low levels, and the main organ producing estrogens is the placenta
[29], which is able to increase the amount of free and conjugated
estrogens (from less than 1 to around 10 ng/mL) starting at 20 days
prior to parturition [29]. Other luteolytic factors, induced by PGF2a,
Table 1 (continued )
Luteotropic
Factors
Pregnancy CL Cyclic CL
Pre-implantation Post-implantation Mid gestation Pre-Partum luteolysis Formation Maintenance Early regression Late regression
CCL13 * * * * * * *
MHCII * * * * * * *
NF-kB (RELA) * * * * constant constant
TNFa ¼ ¼ ¼ ¼
TNFR1 ¼ ¼ ¼ ¼
TNFR2 ¼ ¼ ¼ ¼
Endothelin 2 ¼ ¼
Endothelin 3 constant expression until constant constant ¼
ETA constant expression until constant expression throughout diestrus
Pre-implantation e days 10e12 of gestation (o.g.); Post-implantation e days 18e25o.g.; Mid-gestation e days 30e45o.g.; Pre-partum luteolysis e days 58e61o.g.; Formation
e day 10 post ovulation (p.o.); Maintenance e days 20 and 30 p.o.; Early regression e day 40 p.o.; late regression e day 60 p.o.; LH e luteinizing hormone; GLUT4/GLUT1 e
facilitative glucose transporters 4 and 1; PGR e nuclear progesterone receptor; ERa/ERb e estrogen receptors a and b; PTGS2 e prostaglandin synthase 2; PTGES e pros-
taglandin E synthase; PGT e prostaglandin transporter; EP2/EP4 e prostaglandin receptors 2 and 4; IL e interleukin; VEGFA e vascular endothelial growth factor A; VEGFR1
and 2e VEGFA receptors 1 and 2; FGF2 e basic fibroblast growth factor; ETB and ETA e endothelin receptors B and A; ECE1 e endothelin converting enzyme 1; IGF1 e insulin
like growth factor 1; IGFR1 e receptor 1 for IGF; PGFM emetabolite of PGF2a; PTGFR e receptor for PGF2a; PGFS e prostaglandin F synthase; CCL 3 and 13 e Chemokine CeC
Motif ligand 3 and 13; MHC II emajor histocompatibility complex class II; NF-kB (RELA) e transcription factor, subunit p65, responsible for activation of NF-kB; TNFae tumor
necrosis factor a; TNFR1 and 2 e receptors 1 and 2 for TNFa. Increased ( ), decreased ( ) or equal (¼) expression in relation to previous stage. * - no information
available.
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apoptotic and immune factors, also contribute to luteolysis of the
bovine pregnancy CL. In the rabbit, E2 is considered the main lu-
teotropic factor, acting through its receptors to maintain the cyclic
CL lifespan [30]. The cyclic rat CL is also considered to be sensitive to
E2 as a luteotropic factor [31], as is the porcine CL [32,33]. Indeed, in
the latter species, E2 seems to play a protective role by increasing
LHR expression and P4 production in the cyclic pig CL, delaying the
onset of PGF2a induced luteolysis [32]. In the human cyclic CL, a
luteotropic role has been attributed to E2 [34], but there is some
dispute about its involvement in luteolysis, mediating apoptotic
events [35].
The role of P4 in modulating CL function is rather autocrine and/
or paracrine, as is the role of E2 for the canine CL. We will discuss
these aspects below, under “Paracrine and Autocrine regulators”.
3. Non-classical endocrine regulators of CL function
Insulin plasma concentrations fluctuated during diestrus in
non-pregnant dogs used for most of the experiments we conducted
in this context [36]. Concentrations of 3.8 mU/ml were found on day
10 p.o., decreasing to around 2 mU/mL on days 20 and 30 p.o,
increasing again up to 5 mU/mL on day 40 p.o. and decreasing again
after they reached 50 p.o. (p < 0.05).
Recently, it was shown that insulin is able to increase glucose
uptake by canine luteal cells through phosphorylated AKT-
dependent glucose transporter 4 (GLUT4) translocation [8], as in-
sulin does in classical insulin-sensitive tissues like skeletal muscle
and adipose tissue [37e40]. GLUT4 is the only facilitative glucose
transporter able to respond to insulin stimulus in white and brown
adipose tissue, as well as in skeletal and cardiac muscles [37]. It also
responds to exercise, increasing glucose uptake [41]. Postprandially
and during exercise, more than 50% of cellular GLUT4 content is
translocated into the plasmamembrane, and the amount of glucose
taken up correlates with this GLUT4 shift in cellular localization as
well as with the physiological state of the tissue or cells [42]. Other
tissues such as the uterus, placenta and CL, in humans, rodents and
domestic animals, have been reported to express GLUT4 protein
and SLC2A4, its encoding mRNA [8,43e46]. Both protein andmRNA
can be differentially modulated during CL development and
regression [8,44], placental age [46] and endometrial phases
[43,45]. Nevertheless, to the best of our knowledge, glucose uptake
under insulin stimulus has only been described for cyclic canine
luteal cells [8], even though other above-mentioned studies
attributed a role to GLUT4 in the functionality of endometrial and
placental tissues on the basis of its expression.
In addition to contributing to glucose uptake by translocating
GLUT4 from the intracellular compartment to the plasma mem-
brane, insulin signaling is also able to increase SLC2A4 transcription
and its translation to GLUT4, as shown in rat muscle cells [47] and
canine luteal cells [8]. These results characterize insulin as playing a
role in modulating canine CL function.
4. Paracrine and autocrine regulators of luteal function
4.1. Steroid hormones
Steroid hormones, especially E2 and P4, play the paramount role
in controlling CL function, not only in the dog [5] but also in cows
[27], humans [48], and pigs [49], among others. Since 2001, it has
been known that E2 and P4 receptors are present in the canine CL
and their expression is modulated during diestrus [5,50] and
pregnancy [51e53]. Non-surgical termination of unwanted dog
pregnancies can be achieved by aglepristone, a P4 receptor (PGR)
blocker [10,54e56].
The canine CL is the only source of steroid hormones during
pregnancy and non-pregnant diestrus, since the placenta is unable
to synthetize them [3,4]. In order to achieve its function, P4 has to
bind to nuclear or membrane receptors. After binding to nuclear
receptors, the P4-receptor complex connects to the promoter re-
gion of target genes, and it may recruit additional transcription
binding factors to initiate or repress transcriptional activity (see
review by Ref. [57]). In canine luteal tissue of pregnant and non-
pregnant dogs, PGR is expressed in a time-dependent manner,
apparently exhibiting an inverse relationship to circulating P4
levels [5,50,53]. Interestingly, PGR is expressed in both luteal and
non-luteal cells. Progesterone plasma levels vary strongly individ-
ually and reach maximum values between days 15e30 p.o [1,9,58].
(values of 25e35 ng/mL, sometimes over 80 ng/mL can be recor-
ded). In the second half of the luteal phase, steroidogenesis slowly
declines until sudden luteolysis occurs before parturition; in non-
pregnant dogs, progressive and protracted CL regression occurs
secondary to fatty degeneration of luteal tissue and in the absence
of a luteolytic signal.
Basal P4 levels of <0.1 ng/mL determine the beginning of
anestrus [2]. The presence of PGR in different populations of cells
within the canine CL implies a broad local regulation of physio-
logical processes. It has been postulated that P4 is able to induce
proliferation of endothelial and stromal cells, suppress immune cell
function [52] and act in a positive feedback over the luteal cells, in
an autocrine manner triggering its own production [53]. The first
half of diestrus, when luteal P4 production achieves full capacity,
displays a plethora of luteotropic factors, including the glucose
transporter 1 (GLUT1), whose expression is triggered by P4 itself
through its own receptor, as shown in murine and human endo-
metrial cells [59], favoring glucose uptake to supply the needs of
the developing, fully secretory CL. GLUT1 was assessed in cyclic
canine CL in the context of hypoxia-regulated genes, and showed a
high correlationwith P4 production in the first half of diestrus [58].
Knockout studies in mice shed light upon PGR functions in the
ovary, resulting in an anovulatory phenotype [60]. However, one
should be careful in extrapolatingmouse data to canine CL function,
because blocking PGR functionality in the dog does not affect
ovulation [61].
In our most recent, as yet unpublished study, the expression of
membrane progesterone receptors (MPGRs) was examined in
pregnant and cyclic canine CL. Overall, diestrus and pregnancy
stages influenced the expression of MPGRs, although expression
patterns differed among PGRMC (P4 membrane receptor compo-
nent) 1, 2, PAQR (class II progestin and adipoQ receptor) 5, 7 and 8.
The combination of data already gathered on PGR functionality and
new data on MPGRs may bring new insights into P4 action in the
canine CL during its maturation, maintenance and regression.
Regarding estrogen actions, two main nuclear receptors have
been described, ERa and ERb, encoded by ESR1 and ESR2 genes,
respectively. ERs are broadly distributed throughout the body [62],
pointing towards dependency of the organism upon estrogens for
achieving homeostasis. ERa and ERb are not always present in the
same organs, but if they are, the ratio of ERa to ERb also plays a role
in the response to estrogens, in a tissue-dependent manner [63].
Moreover, when expressed together, ERa and ERb heterodimerize
[64]. More recent data indicate that, whereas homofusion of either
ERa or ERb evokes signals similar to the parent ER, heterodimers
emulate the transduction effects of ERa, affirming the latter as the
dominant partner in the ERa/ERb dimer [65].
In the canine cyclic CL, both ERa and ERb are expressed [5,50],
and predominantly found in steroidogenic cells, while being less
represented in non-steroidogenic cells. The mRNA and protein
expression levels of ERa appear to diverge [5,50]. The ERa protein
was found consistently distributed in luteal and non-luteal cells
during diestrus, but in luteal cells a gradual increase from day 35
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and elevated expression on day 65 were observed [5]. In contrast,
the transcripts levels were elevated from day 5 to day 25, and
decreased gradually towards day 65 p.o [5]. The expression of ERb
and ERS2, however, was not greatly affected by the stage of diestrus
[5]. However, in another recently published study, the transcript
levels of both ESR1 and ESR2 were also investigated in the CL of
non-pregnant dogs, both showing time-dependent effects and
increased expression towards day 30 p.o [66]. Interestingly, despite
high individual variations in that study, their expression was not
affected by functional withdrawal of prostaglandins [66]. Never-
theless, taking into consideration the expression and distribution
patterns of the respective proteins, ERa and ERb, cumulatively the
available data imply that the ratio of ERa to ERb may change with
increasing ERa expression towards the end of diestrus [5,50].
Additionally, estrogen sulphotransferase 1 (SULT1), an enzyme
responsible for conjugation and inactivation of estrogens, was
found to be increased during luteal regression of the cyclic canine
CL on day 65 p.o. compared to pre-partum luteolysis in pregnancy
CLs of the same age, which was interpreted as a sign of a functional
withdrawal of estrogens [52]. Notably, SULT1 was among the genes
commonly upregulated in luteolytic dogs, both during natural
luteolysis and in mid-pregnant dogs in which luteolysis/abortion
was induced by an antigestagen [52]. The latter finding implies a
role of PGR in mediating the local availability of estrogens, making
estradiol unavailable for its otherwise expressed receptors.
As described for rat Sertoli cells [67], the functions of 17b-
estradiol, if transferred to the CL, could be related to proliferative as
well as anti-proliferative processes, and this would indeed depend
on the ERa/ERb ratio as already described for human breast cancer
cells [68]. Moreover, the description of membrane-bound estrogen
receptors in the hamster ovary, the ESR36 [69], a splice variant of
the ESR1 gene involved in non-genomic signaling of estrogens,
leads us to assume that E2 action in follicles is broader than orig-
inally presumed. Although currently there are no data addressing
the presence of membrane-bound estrogen receptors in CLs, their
contribution to the regulation of luteal function warrants further
investigation.
Additionally, nuclear ERs have been related to metabolic disor-
ders. Insulin resistance increases in muscle cells treated with ERb
agonist, whereas ERa shows a protective effect for insulin resistance
and obesity [70,71]. Often driven by the estrous cycle and preg-
nancy, hormone fluctuations may lead to impairment of glucose
metabolism and insulin resistance in humans, and ERs have been
implicated in this process [72]. Whenwe consider that insulin plays
a luteotropic role in the canine CL [8], fluctuations of ERs in the
tissue could also have an effect on insulin-driven GLUT4 glucose
uptake.
And last, but not least, the priming action of E2 in the canine CL
for the expression of PRL and, reciprocally, for PGR [17], attributes
another critical autocrine and paracrine role to E2.
4.2. Prostaglandins
Prostaglandin F 2a (PGF2a) is the most-studied PG in domestic
animals, and its main function is termination of the luteal phase in
non-pregnant females to allow resumption of cyclicity. In rumi-
nants, PGF2a originates in the uterus and acts on the CL by a
counter-current mechanism involving the uterine vein and the
ovarian artery. In the non-pregnant dog, PGF2a does not seem to
play a physiological role in CL regression [9,73]. Expression of the
PGF2a-synthase (PGFS) enzyme is very low or absent in both
pregnant and non-pregnant canine CL [74,75]. Nevertheless, due to
its constitutive expression of the respective receptor, PTGFR [53,74],
the canine CL remains responsive to exogenously administered
PGF2a [76e78]. However, as reported, e.g., for early pregnant
bitches, serious dose-dependent adverse side effects, mainly
related to emesis and induction of defecation, are to be expected
[77]. In contrast to non-pregnant dogs which lack endogenous
PGF2a secretion by the uterus, the utero-placental unit of pregnant
bitches secretes PGF2a that leads to pre-partum luteolysis [9,10,79].
It originates predominantly from the microsomal compartment of
fetal trophoblast cells in the placenta, and triggers contractility of
the myometrium and apoptosis of luteal cells [10,75].
As for PGE2, it seems to be the most important prostaglandin
controlling early CL function in dogs. It acts as a luteotropic factor
directly involved in CL formation and P4 production [73], as well as
indirectly by increasing blood flow and enhancement of PRL re-
ceptor [66,80]. The whole machinery necessary for PGE2 synthesis
and action in the dog is present in both pregnant and non-pregnant
CLs. It starts with a massive expression of cyclooxygenase 2 (PTGS2)
and the converting enzyme PGE2 synthase (PTGES)when P4 plasma
levels are rising [81], associated with the expression of the PG
transporter (PGT). The expression of HPGD, an enzyme responsible
for PGs degradation, is negatively correlated with PTGES and PGT.
Moreover, when PTGS2 is blocked in vivo following the use of the
selective COX2 blocker firocoxib, an inhibition of STAR and HSD3B
accompanied by reduced P4 concentrations is observed [82,83]. In a
follow-up study, also including the RNAseq approach on CL tissues
from non-pregnant dogs treated with firocoxib from day 5e30 p.o.,
Tavares Pereira and collaborators [66,84] documented the expres-
sion of genes related to immune system, vascularization and general
global luteal transcriptomic changes. Genes belonging to the
angiopoietin family (ANGPT) were down-regulated, whereas
endothelin 1 and some pro-inflammatory cytokines, e.g., IL1b, IL6
and IL12a, were increased. The up-regulation of the above-
mentioned cytokines by a COX2 inhibitor points to a possible
immunosuppressive effect of PGs in the canine cyclic CL [66,84]. The
findings regarding the ANGPTs and their receptors indicate a
destabilization of blood vessels when PGs are not available.
4.3. Cytokines
Cytokines have been brought into focus in the regulation of CL
function only in recent decades, when several immune cells, e.g.,
lymphocytes, macrophages, plasmocytes and dendritic cells, have
been reported to secrete theircytokineproducts in theCLof cattle and
other species, affecting its function (see review by Ref. [85]). Addi-
tionally, recently, specific subsets of miRNA have been implicated in
cytokine-mediated regulation of cyclic and pregnancy CLs in cattle
[86]. In the canineCL, the expressionof cytokineswas reported for the
first time in the studies of Hoffmann and collaborators [50,87,88].
Although thepresenceofCD4þ andCD8þ immunecellswas identified
within the canine CL, at that time only a few cytokines, e.g., inter-
leukin- (IL) 8,10 and12, TNFa andTGFB1were differentially regulated
throughout diestrus and, thus, implicated in the regulation of CL
function [88]. Using qPCR and RNA sequencing, it has recently been
shownthatexpressionof other cytokines is alsomodulated according
to the phase of diestrus in the canine cyclic andpregnant CL [8,66,84].
Whereas pro-inflammatory cytokines such as IL-1b and IL-12a donot
exhibit time-dependent expression in the first half of the cyclic CL
lifespan, IL-10 and IL-6 show up-regulation on days 10 and 20 p.o.,
respectively [8,66]. When luteal tissue samples from non-pregnant
dogs in late diestrus were compared with luteal samples from dogs
undergoing pre-partum luteolysis using next-generation RNA
sequencing,1595 differentially expressed genes (DEG) were detected
[52]. Gene expression in prepartum luteolysis pointed towards an
acute immune and inflammatory response, represented bymassively
increasedexpressionof IL-1b, chemokine (CeCmotif) ligand3 (CCL3),
major histocompatibility complex class II (MHCII) and chemokine
(CeC motif) ligand 13 (CCL13). In contrast, the transcriptome of CL
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samples from non-pregnant dogs provided evidence for luteal
regression to be characterized as a prolonged, degenerative process
without involvement of significant immune response. In another
study [89], TNFA and its two receptors were detected during the
wholeofdiestrus inbothpregnantandnon-pregnantCLs. In the cyclic
canine CL, the expression patterns of TNFA, TNFR1 and TNFR2 were
the same as in the CLof pregnancy, decreasing fromday 5until day 35
p.o and remaining low until day >65 p.o.
4.4. Growth factors
Several families of growth factors have been reported as present
in the canine CL, as described below. Some of their functions in the
CL encompass capillary bed formation and maintenance, cell pro-
liferation and migration and steroidogenesis. The CL is a temporary
endocrine gland, the formation of which relies on angiogenesis, and
regression/luteolysis upon withdrawal of its vascular bed. It de-
pends on a finely-tuned synchronization among different vascular-
related growth factors. VEGFA and its receptors (VEGFR1/FLT1 and
2/KDR) have been localized to luteal and endothelial cells
throughout diestrus [90] and their expression changed according to
the luteal phase. The highest mRNA expression of VEGFA and its
two receptors was on day 20 p.o., although VEGFR2 showed
another peak of expression on day 40 p.o [58]. It is known that
when VEGFA binds to VEGFR2, a positive proliferation response
occurs, whereas the binding to VEGFR1 leads to a sequestration of
the available VEGFA, impairing the binding to VEGFR2 [91]. More-
over, VEGFA and FGF2 have been shown to increase steroidogenesis
through increased expression of STAR in the bovine CL [92], a fact
that led us to speculate if this could also be true for the canine CL,
since the highest expression of STAR occurs concomitantly with P4
secretion. FGF2 mRNAwas also assessed in the canine cyclic CL and
it showed fluctuations during diestrus, increasing from day 10 to
day 30 p.o. (maximum expression) and declining towards day 70
p.o [58]. In the canine CL of pregnancy, VEGFA and its two receptors
were also studied [93] at specific time points. Similarly, as in
pregnant dogs, the highest VEGF and VEGFR1 expression was
observed in early until fully mature CLs, compared with later luteal
stages, corresponding to the time of increasing P4 secretion [93].
The expression of VEGFR2 did not vary strongly throughout preg-
nancy. The stable expression of VEGFR2 may indicate the need for
VEGFA signaling also when the pregnant canine CL starts its
remodeling towards pre-partum luteolysis.
Endothelins (ETs: ET1, ET2 and ET3) belong to another growth
factor family involved in vascularization of the canine CL. They bind
to two receptors, ETA and ETB, whose activation results in opposite
actions: binding to ETA leads to vasoconstriction while binding to
ETB to vasodilatation. ETs have also been shown to induce P4
secretion in cows [94]. Gram and collaborators [80] reported time-
dependent expression of ETs, their receptors and their converting
enzyme (ECE1) in canine cyclic and pregnant CLs. Cyclic CL devel-
opment was associated with strong expression of ETB, ECE1 and
ET2, which decreased towards the mid and late luteal phases. Pre-
partum luteolysis was characterized by higher expression of ET2
and ET3 as well as of ETA. This difference of expression between
canine pregnant and cyclic CL may be due to the response to PGF2a,
derived from the utero-placental compartment, actively vaso-
constricting blood vessels and contributing to a rapid termination
of pregnant CL function [80].
The IGF1 and its receptor IGF1R belong to another family of
growth factors, the insulin-like growth factors, which have been
studied in the canine CL [95]. As already postulated for cows [96],
IGF1 and its receptor have been proposed to act as paracrine and
autocrine factors within cyclic and pregnant canine CLs, since they
were co-localized in luteal and endothelial cells. Moreover, their
mRNA expression pattern differed: in cyclic CL, IGF1 expression
decreased on days 45 and 65 p.o. and IGFR1 remained unchanged,
whereas in the pregnant CL there was a constant decrease from
pre-implantation until pre-partum luteolysis and IGFR1 increased
at pre-partum luteolysis [95], indicating a response to PGF2a, as
previously shown in cows [97].
5. Perspectives
The more than 15,000-year successful partnership between
dogs and humans [98] has placed the dog as a family member in
many societies, launching the concept of a multi-species family,
which nowadays is also shared by cats, with all the bonuses and
onuses [99].
On the one hand, developed countries have achieved a high
degree of dog welfare conditions, but the concern remains that
some breeds, which developed based on their phenotype, are not
able to reproduce. On the other hand, most countries still face
problems of poor animal welfare conditions, including uncon-
trolled stray and feral populations of dogs and cats. So, ultimately,
should we conduct research in order to increase or to avoid canine
reproduction? The quest to find non-surgical methods to safely
manipulate reproduction in dogs is of paramount importance.
Given the above analyses and understanding of luteotropic and
luteolytic factors governing cyclic and pregnant canine CL lifespans,
we can infer that more research is necessary to terminate an un-
wanted pregnancy at its beginning, i.e., to decrease P4 levels so that
the CL is not able to achieve its full secretory capacity. Surgical
procedures are available but not always desired, since they are
invasive and permanent. Possible targets for that purpose, in the
first half of diestrus, have to be identified among the upstream
regulators of steroidogenesis and P4 receptors (PGRs), before PGR is
activated and triggers the positive feedback loop of its own
expression and P4 production. Candidates could be genes and
proteins related to the first supply of energy to the CL, such as
SLC2A1/GLUT1 and insulin receptor (INR), and related also to vas-
culogenesis, such as VEGFA and its receptors. Nevertheless, one
should keep inmind that the blockade of these genes, which showa
whole body distribution, has to be local. We could take advantage
of already developed research in cancer, where the use of targeted
gene therapy is a reality [100]. Additionally, if our aim is to prevent
a pregnancy in canines, we could locally target as early as the
luteinization process of granulosa cells [101], depleting their
nutritional supply and/or inducing their apoptosis, then avoiding
ovulation without the use of hormone-related treatments, which
are very deleterious for bitches [102,103]. To corroborate our line of
thought, a recent publication by Rhodes [104] addressed the ne-
cessity of sterilizing dogs and cats using non-hormone and non-
surgical approaches that are as permanent as possible. It is our
hope that this review could contribute to devise strategies for
developing new molecular-based drugs.
On the contrary, if our aim is to promote pregnancy in dogs,which
sometimes is not successful due to luteal insufficiency [13,105], this
review discusses a plethora of luteotropic factors that could be tar-
geted locally in the first half of pregnancy, which would be able to
stimulate luteal P4 production, as for example, PGE2, transcription
factors associated with PGR signaling, growth factors and IL-10,
among others. The use of exogenous P4 for this purpose has been
reported as well [106], but its efficacy cannot readily be determined.
Because the canine CL exhibits somany local factors regulating its
function and lifespan, and because modern biotechnology offers
diverse possibilities for manipulating themwithout affecting overall
general health of the animals, we recommend investing in devising
approaches to regulate the canine CL function at the local level.
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